Moderator
Dr Min-Hee Hong, MD
Associate Professor,
Division of Medical Oncology, Department of Internal
Medicine, Yonsei Cancer Center, Severance Hospital,
Yonsei University College of Medicine,
Seoul, Korea
Explore the webinar series by selecting the dropdown
No time to wait:
Evolving testing & treatment landscape in early stage lung cancer
EXPERT SERIES
No time to wait:
Evolving testing & treatment landscape in early stage lung cancer
10th of August 2022
14:00 - 15:00 GMT +8
Lung cancer has seen tremendous advancements over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors. Until recently these advances were predominantly in the advanced metastatic setting. The approvals of osimertinib, the first targeted therapy directed against EGFR for adjuvant use and atezolizumab, the first immune-checkpoint inhibitor to be FDA-approved for adjuvant use have brought much needed advancement in the post-operative setting. Please join our live webinar on 10th August to hear thoracic multidisciplinary teams of pathologists, surgeons and oncologists from Korea and Thailand share updates in the testing and treatment setting for early stage non-small cell lung cancer.
Who should attend:
- Oncologists, Pulmonologists, Pathologists, Thoracic surgeons, Pathology lab directors, Diagnostics Labs, GPs, HCPs with a general interest in oncology diagnostics
Key reasons to attend:
- Get updates on the current testing and treatment practices for early stage non-small cell lung cancer
- Learn differing testing approaches from multiple institutions in APAC
- Hear from a thoracic surgeon and pathologists on best practices to manage limited tissue and optimal timing of testing
- Get a multidisciplinary perspective on the best patient management practices in the post-operative setting
Faculty
MODERATOR
Dr Min-Hee Hong, MD
Associate Professor,
Division of Medical Oncology, Department of Internal
Medicine Yonsei Cancer Center, Severance Hospital
Yonsei University College of Medicine
Seoul, Korea
|
|
Dr. Min-Hee Hong is an Associate Professor at the Department of Internal Medicine at Yonsei Cancer Center in Seoul, Korea. He received his medical degree and completed his residency training at Yonsei University College. Following his residency, Dr. Hong completed a fellowship in the division of medical oncology. In 2015, he worked as a Medical Advisor for Merck and is currently serving as the Vice Managing Director of Esophageal Cancer Center at Yonsei Cancer Center in Yonsei Cancer Center, Severance Hospital. Dr. Hong is part of a cooperative group that actively conducts cancer research in various therapeutic areas. He is a member of The International Association for the Study of Lung Cancer. His current academic interests include lung cancer, esophageal squamous cell carcinoma, and squamous cell carcinoma of the head and neck as well as investigating molecular targets and immunotherapies.
SPEAKER
Dr Tae-Jung Kim
Professor, Department of Hospital Pathology,
Yeouido St. Mary's hospital,
The Catholic University of Korea,
Seoul, Korea
SpeakerDr Tae Jung Kim
Professor, Department of Hospital Pathology, |
Dr Tae Jung Kim is the Professor and Chair of the Pathology Department at Yeouido St. Mary's Hospital. His pathology department currently serves as the largest central laboratory in South Korea. Dr. Kim received his medical degree from the Catholic University of Korea in 2003, where he also completed his residency training in 2008. Dr. Kim was a research scholar at M.I.T and Dana Farber Cancer Institute at Harvard Medical School in Boston, Massachusetts, US. His primary research interests are companion diagnostics and therapeutic biomarkers in lung cancer.
SPEAKER
Dr Pimpin Incharoen, MD
Assistant Professor, Department of Pathology
Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
SpeakerDr Pimpin Incharoen, MDAssistant Professor, Department of Pathology |
Pimpin Incharoen, MD, is an assistant professor at the department of pathology at Ramathibodi Hospital at Mahidol University in Bangkok, Thailand. She received her medical degree in 2005 from Chulalongkorn University also in Bangkok, Thailand. She did her residency training in Anatomical Pathology at Siriraj Hospital at Mahidol University. Between 2013 and 2014, Dr. Pimpin was a visiting fellow in thoracic pathology at the University of Pittsburgh Medical Center, in Pennsylvania, USA where she was trained in advanced histochemistry, immunohistochemistry, and molecular biological techniques in the clinical and pathologic diagnosis of lung cancer. Dr. Pimpin’s clinical interests include analyzing the immunologic profile and unique molecular characteristics of lung adenocarcinoma in the Thai patient population.
SPEAKER
Dr Somcharoen Saeteng
Associate Professor,
Thoracic Surgeon
Chiang Mai University
Chiang Mai, Thailand
SpeakerDr Somcharoen Saeteng Associate Professor,
Thoracic Surgeon |
Associate Professor, Somcharoen Saeteng has been a Thoracic Surgeon at Chiang Mai University for almost 30 years. He graduated with a Medical Degree from Chiang Mai University in 1994. After medical school, Dr. Somchareon traveled to Hong Kong and Japan to develop his specialty as a thoracic surgeon. He returned back to Chiang Mai as a pioneer in minimally invasive surgery in northern Thailand. Dr. Somchareon’s clinical interests include novel treatment approaches in lung cancer. He has extensive clinical trial experience in global lung cancer studies, including neo-adjuvant and adjuvant lung cancer trials.
Did you miss the last webinars? Watch the recordings here
Why participate?
Lung cancer is one of the most common and deadly forms of cancer in APAC. As early diagnosis is key for the best chances of survival, we are partnering with multiple stakeholders to educate healthcare professionals on a series of personalised healthcare topics. We can combat cancer together and improve patients’ lives.
Lung cancer is one of the most common and deadly forms of cancer in APAC. As early diagnosis is key for the best chances of survival, we are partnering with multiple stakeholders to educate healthcare professionals on a series of personalised healthcare topics. We can combat cancer together and improve patients’ lives.
EXPERT SERIES
13th December
18:30 - 19:30 (GMT+8)
The field of clinical oncology continues to see drastic advancements with non-invasive techniques, such as liquid biopsy being adopted for diagnosing and monitoring cancers in place of more invasive methods. Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients with cancer. Liquid biopsies have the potential to change the diagnostic and prognostic landscape for cancer genotyping and impact patient management. However, several limitations still hamper the implementation of liquid biopsy in clinical practice.
Register to learn how liquid biopsies may help with treatment selection and monitoring of cancer treatment outcomes and the current challenges limiting clinical practice adoption.
Who should attend:
- Oncologists, Pulmonologists, Pathologists, Thoracic surgeons, Pathology lab directors, Diagnostics Labs, GPs, HCPs with a general interest in oncology diagnostics
Key reasons to attend:
- Get updates on the exciting advances of liquid biopsy as a tool to aid in cancer diagnosis and inform treatment decisions.
- Learn about the clinical applications of ctDNA in early-stage cancer in terms of detection of minimal residual disease and molecular relapse monitoring.
- Learn about the potential and limitations of liquid biopsy-based tumor genomic profiling.
Faculty
Moderator
Dr. Stephen Wong
Head of the Cancer Genomics Translational Research Centre
Peter MacCallum Cancer Centre,
Australia
ModeratorDr. Stephen Wong
Head of the Cancer Genomics Translational Research Centre
Peter MacCallum Cancer Centre, |
Dr. Stephen Wong is Head of the Cancer Genomics Translational Research Centre at the Peter MacCallum Cancer Centre. He is a fellow of the Royal College of Pathologists of Australasia, a recipient of an NHMRC Emerging Leader Fellowship and a Victorian Cancer Agency Mid-Career Fellowship. He oversees the design, development and coordination of multiple translational research projects for both academic and commercial partners using a range of cutting-edge genomic-based methodologies. His current research interests include the application of circulating tumour DNA across multiple cancer types and has worked towards the clinical translation of ctDNA analysis into clinical practice.
Speaker
Dr. Lavinia Tan
Medical Oncologist
Peter MacCallum Cancer Centre,
Australia
SpeakerDr. Lavinia Tan
Medical Oncologist |
Lavinia obtained her undergraduate medical degree from the University of Melbourne and completed her specialist training in medical oncology and a clinical fellowship focusing on lung cancer through the Royal Australian College of Physicians. Lavinia is completing her PhD in the Molecular Biomarkers and Translational Genomics Laboratory exploring the utility of circulating tumour DNA to guide precision medicine in solid malignancies. She currently practices as a Medical Oncologist at the Peter MacCallum Cancer Centre with a focus on clinical and translational research.
Speaker
Prof. Natasha Leighl
Thoracic Medical Oncology Group Lead
Princess Margaret Cancer Centre,
Canada
Professor, Department of Medicine
Adjunct Professor, Institute of Health Policy,
Management and Evaluation
University of Toronto,
Canada
ModeratorProf. Natasha Leighl
Thoracic Medical Oncology Group Lead |
Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published over 350 peer-reviewed papers, has held (as principal or co-investigator) over $800 million in peer-reviewed grant funding. She has mentored many trainees that have gone on to leadership roles in oncology around the world, and received the American Society of Clinical Oncology Excellence in Teaching Award in 2019.
Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics including liquid biopsy. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, a member of the IASLC Quality and Value Committee, on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board, and is Past President of Lung Cancer Canada.
Did you miss the last webinars? Watch the recordings here
Lung Cancer Diagnostics Post COVID - a Multidisciplinary View
Oncology Diagnostics Webinar Series 1
The importance of EGFR CDx testing and recent treatment updates in early stage NSCLC
Oncology Diagnostics Webinar Series 2
Clinical Utility of Liquid Biopsy in EGFR testing for Lung Cancer
Oncology Diagnostics Webinar Series 3
Connecting Oncology and Pathology in the personalized care of NSCLC patients
Oncology Diagnostics Webinar Series 4
Digital Tools to Drive NGS Clinical Application for the Future
Oncology Diagnostics Webinar Series 5
Why participate?
Lung cancer is one of the most common and deadly forms of cancer in APAC. As early diagnosis is key for the best chances of survival, we are partnering with multiple stakeholders to educate healthcare professionals on a series of personalised healthcare topics. We can combat cancer together and improve patients’ lives.
Lung cancer is one of the most common and deadly forms of cancer in APAC. As early diagnosis is key for the best chances of survival, we are partnering with multiple stakeholders to educate healthcare professionals on a series of personalised healthcare topics. We can combat cancer together and improve patients’ lives.